AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

Group 1 - AIM ImmunoTech Inc. announced the closing of a public offering of 2,000,000 shares of common stock and accompanying warrants at a combined public offering price of $4.00 per share, resulting in gross proceeds of approximately $8.0 million before expenses [1][2][3] - The offering included Class E and Class F warrants, both of which are exercisable immediately upon issuance, with Class E warrants expiring on the fifth anniversary and Class F warrants expiring on the eighteen-month anniversary of the original issuance date [1] - Maxim Group LLC acted as the sole placement agent for this offering [2] Group 2 - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), which is a first-in-class investigational drug with broad-spectrum activity in clinical trials [4]